Effect of Landiolol Hydrochloride on Hemodynamics in a Histamine-Induced Shock Model

Masaharu Hirano1, Tatsuaki Okamura2, Tetsuji Nagano3

  • 1Department of Cardiology, Tokyo Medical University, 6-7-1, Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. m-hirano@tokyo-med.ac.jp.

Drugs in R&D
|June 15, 2021
PubMed

Insights

Anaphylactic shock during coronary CT angiography can be treated by increasing doses of epinephrine and glucagon in patients taking beta-blockers. This approach mitigates hemodynamic instability, ensuring patient safety during the procedure.

Area of Science:

  • Cardiology
  • Pharmacology
  • Radiology

Background:

  • Anaphylactic shock is a severe adverse drug reaction to contrast media used in coronary computed tomography angiography.
  • Beta-blockers improve coronary computed tomography angiography imaging by reducing heart rate.
  • Short-acting beta-1 blockers are often used in this context.

Purpose of the Study:

  • To analyze anaphylactic shock treatment in patients receiving short-acting beta-1 blockers.
  • To investigate the efficacy of epinephrine and glucagon in managing hemodynamic changes during beta-blocker treatment.

Main Methods:

  • A dog histamine shock model was utilized to simulate anaphylactic shock.
  • The effects of landiolol hydrochloride (a beta-1 blocker) on hemodynamics were assessed.
  • The influence of epinephrine and glucagon on hemodynamic parameters during landiolol treatment was examined.

Main Results:

  • Landiolol decreased mean blood pressure and heart rate, and reduced histamine-mediated increases in cardiac contraction force.
  • Histamine shock led to hemodynamic deterioration in subjects receiving landiolol.
  • Increasing doses of epinephrine and glucagon effectively ameliorated the shock-induced hemodynamic deterioration.

Conclusions:

  • Elevated doses of epinephrine and glucagon can mitigate hemodynamic deterioration from anaphylactic shock in patients on landiolol for coronary computed tomography angiography.
  • Clinicians should ensure adequate supplies of epinephrine and glucagon are available before performing coronary computed tomography angiography.
Abstract

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
840
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
635
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
538
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
869
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.1K